9604472c-4956-4170-8ba7-419f3e8d7418
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- PANCREAS_BETA_CELLS+0.300
- TGF_BETA_SIGNALING+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- HYPOXIA+0.200
- IL6_JAK_STAT3_SIGNALING+0.200
- KRAS_SIGNALING_UP+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- ALLOGRAFT_REJECTION+0.100
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- ADIPOGENESIS-0.400
- PEROXISOME-0.400
- PROTEIN_SECRETION-0.400
- BILE_ACID_METABOLISM-0.300
- CHOLESTEROL_HOMEOSTASIS-0.300
- HEME_METABOLISM-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_C41DJZ1F | high-grade glioma | — | 0.821 |
| 2 | DRR168520 | — | — | 0.776 |
| 3 | 1ae8df2d-8c7c-474d-9208-ea63784edc90 | — | — | 0.771 |
| 4 | 156a3def-5866-4be4-ad0b-61b957d5b6eb | — | — | 0.748 |
| 5 | SRR23303757 | — | — | 0.748 |
| 6 | TCGA-CN-6022-01A-21R-1686-07 | — | — | 0.742 |
| 7 | 824433bf-151c-46ea-9ea7-f53813f66a97 | — | — | 0.737 |
| 8 | 1fd89d3a-5991-4bfb-b27f-66b5f2a289d8 | — | — | 0.726 |
| 9 | TCGA-55-8614-01A-11R-2403-07 | — | cohortSQ1 | 0.725 |
| 10 | TCGA-EW-A6SC-01A-12R-A32P-07 | — | A | 0.723 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |